Alcohol Use in Patients with Chronic Liver Disease

To the Editor: In the review article by Fuster and Samet (Sept. 27 issue) 1 regarding alcohol use in patients with chronic liver disease, the authors rightly consider short-acting benzodiazepines (oxazepam and lorazepam) to be the cornerstone of treatment for the alcohol withdrawal syndrome. In addi...

Full description

Saved in:
Bibliographic Details
Published inThe New England journal of medicine Vol. 379; no. 26; pp. 2577 - 2579
Main Authors Caputo, Fabio, Zoli, Giorgio, Bernardi, Mauro, Rathi, Sahaj, Singh, Akash, Singh, Virendra, Fuster, Daniel, Samet, Jeffrey H
Format Journal Article
LanguageEnglish
Published United States Massachusetts Medical Society 27.12.2018
Subjects
Alcohol use
FDA approval
Liver diseases
Lorazepam
Patients
Sodium
γ-Aminobutyric acid
Italy
Austria
Online AccessGet full text
ISSN0028-4793
1533-4406
1533-4406
DOI10.1056/NEJMc1814129

Cover

More Information
Summary:To the Editor: In the review article by Fuster and Samet (Sept. 27 issue) 1 regarding alcohol use in patients with chronic liver disease, the authors rightly consider short-acting benzodiazepines (oxazepam and lorazepam) to be the cornerstone of treatment for the alcohol withdrawal syndrome. In addition, γ-aminobutyric acid (GABA) compounds that have not been approved by the Food and Drug Administration were discussed as potential alternatives. We think that the GABA type B receptor agonist sodium oxybate, which has been approved for the treatment of the alcohol withdrawal syndrome in Italy and Austria for more than 20 years, merits mention. 2 It . . .
Bibliography:SourceType-Scholarly Journals-1
ObjectType-Correspondence-2
content type line 14
ObjectType-Letter to the Editor-1
ObjectType-Correspondence-1
ObjectType-Commentary-2
content type line 23
ISSN:0028-4793
1533-4406
1533-4406
DOI:10.1056/NEJMc1814129